Menu
1 min read · estimated
APPROVED USE
What FDA approved
For adults and children age 12 years or older with previously treated, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic.
LAMPGEN ANALYSIS
Why it matters
The CABINET study evaluated separate pancreatic and extra-pancreatic cohorts under the same kinase inhibitor program.
What research teams should watch
Record the primary tumor site and differentiation and map dose modifications to the applicable formulation and age group.
PRIMARY RECORDS